STTK — Shattuck Labs, Inc.

Summary of Shattuck Labs Q3 2023 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2023, Shattuck Labs reported cash and cash equivalents of $101.1 million.
• Expenses: Research and development expenses increased to $24.2 million from $18.9 million in Q3 2022. General and administrative expenses decreased to $5.1 million from $6.6 million year-over-year.
• Net Loss: The net loss for Q3 2023 was $27.5 million, or $0.65 per share, compared to a net loss of $24.6 million, or $0.58 per share, in Q3 2022.
• Cash Runway: The company believes its current cash position is sufficient to fund operations through the end of 2024.

2. Strategic Updates and Business Highlights

• Clinical Progress: Shattuck's lead candidate, SL-172154, has shown promising early clinical data in both hematologic and solid tumor indications.
  • In the Phase 1B trial for platinum-resistant ovarian cancer (PROC), an overall response rate of 27% was observed, significantly higher than the historical benchmark of 4% for PLD monotherapy.
  • In the Phase 1A/B trial for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS), initial responses were noted, with ongoing enrollment in frontline cohorts.
• Differentiation: SL-172154 is designed to avoid common safety issues associated with other CD47 inhibitors, such as destructive anemia, enhancing its potential therapeutic profile.

3. Forward Guidance and Outlook

• Upcoming Milestones: Shattuck plans to present complete data from the dose escalation portion of its AML/MDS trial at the ASH Annual Meeting in December 2023 and initial data from frontline cohorts shortly thereafter.
• Enrollment Goals: The company expects to complete enrollment in its ongoing trials by the end of Q4 2023 and aims to provide further updates on response rates and durability in mid-2024.

4. Bad News, Challenges, or Points of Concern

• Competitive Landscape: The CD47 pathway has seen skepticism due to safety issues with other agents, which could impact investor sentiment and market perception.
• Enrollment Challenges: Initial enrollment in the PROC study was slow, attributed to the perception of PLD's limited efficacy, although momentum has improved with recent data.
• Clinical Risks: The outcomes of ongoing trials will be critical; failure to meet expected response rates could hinder future development and market opportunities.

5. Notable Q&A Insights

• Patient Characteristics: The majority of patients in the PROC trial had received multiple prior therapies, including platinum and bevacizumab, indicating a challenging patient population.
• Response Kinetics: Early responses were observed within the first cycle of treatment, suggesting rapid kinetics which could be advantageous for patient outcomes.
• Regulatory Pathways: There is potential for accelerated approval in specific cohorts, such as TP53 mutant AML, if response rates exceed benchmarks significantly.
• Biomarker Analysis: The company is collecting biomarker data to potentially inform patient selection strategies in future studies.

Overall, Shattuck Labs is making significant strides in its clinical programs, with promising early data for SL-172154, while navigating challenges in a competitive landscape and the need for continued positive clinical outcomes.